[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3493 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 3493
To reduce prescription drug prices by aligning U.S. prices with
international benchmarks.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 19, 2025
Mr. Khanna (for himself, Mrs. Luna, Ms. Kaptur, and Mr. Biggs of
Arizona) introduced the following bill; which was referred to the
Committee on Energy and Commerce, and in addition to the Committees on
Ways and Means, and the Judiciary, for a period to be subsequently
determined by the Speaker, in each case for consideration of such
provisions as fall within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To reduce prescription drug prices by aligning U.S. prices with
international benchmarks.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Global Fairness in Drug Pricing
Act''.
SEC. 2. DRUG PRICING.
(a) Most-favored Nation Price Targets.--Not later than 30 days
after the date of enactment of this Act, the Secretary of Health and
Human Services shall, in coordination with the Administrator of the
Centers for Medicare & Medicaid Services and other heads of relevant
Federal agencies--propose a rulemaking plan to impose most-favored-
nation price targets to pharmaceutical manufacturers to ensure that
prices for pharmaceutical products paid by patients in the United
States are comparable to the prices for such products paid by
comparably developed countries.
(b) Importation by Individuals.--The Secretary of Health and Human
Services shall certify to Congress that importation under section
804(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384(j))
will pose no risk to the health and safety of the public and will
result in a significant reduction in the cost of prescription drugs to
the American patients in the United States; and the Secretary of Health
and Human Services shall take action under section 804(j)(2)(B) of such
Act to describe circumstances under which waivers will be consistently
granted to individuals to import prescription drugs, on a case-by-case
basis, from developed countries with low-cost prescription drugs.
(c) Enforcement Actions.--The Attorney General and the Chair of the
Federal Trade Commission shall, to the extent consistent with law,
undertake enforcement action against any anticompetitive practices by
pharmaceutical manufacturers, including through enforcement of sections
1 and 2 of the Sherman Act (15 U.S.C. 1, 2) and section 5 of the
Federal Trade Commission Act (15 U.S.C. 45), as appropriate.
(d) Programs Enabling Direct-to-Consumer Purchases.--To the extent
permitted by law, the Secretary of Health and Human Services shall
facilitate direct-to-consumer purchasing programs for pharmaceutical
manufacturers that sell their pharmaceutical products to patients in
the United States at the prices determined through the rulemaking under
subsection (a).
(e) Study of Unreasonable or Discriminatory Behaviors of
Manufacturers.--The Secretary of Commerce and the United States Trade
Representative shall conduct a study to determine whether any act,
policy, or practice by pharmaceutical manufacturers constitutes
unreasonable or discriminatory behavior that--
(1) impairs national security;
(2) forces patients in the United States to subsidize
global pharmaceutical research and development; or
(3) involves suppression of drug prices in foreign markets
below fair market value.
The findings of such a study shall be submitted in a report to Congress
not later than 180 days after the date of the enactment of this Act.
<all>